Menu
Recruiting NCT07343297

Ask Questions About Clinical Trials

No phase Interventional Oncology Cardiac Disease Neurologic Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ask Questions about Clinical Trials brochure.
Who it may be relevant to
Registry conditions: Oncology, Cardiac Disease, Neurologic Disorder. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Ask Questions About Clinical Trials (ASQ - CT): An Implementation Trial of a Communication Intervention to Improve Patient-Provider Communication About Clinical Trials and Provider Invitations to Clinical Trials

Overview

The overall goal of this study is to assess the implementation of the Ask Questions about Clinical Trials (ASQ-CT) brochure, a patient-focused communication tool previously demonstrated to improve patient-provider communication about clinical trials. Participants will be given the ASQ-CT brochure at Time 1 (baseline) and participants will complete a questionnaire at three timepoints, baseline (Time 1), Pre-Research Visit (Time 2), and Post-Research Visit (Time 3).

Interventions

  • Behavioral Ask Questions about Clinical Trials brochure
    Communication intervention called a question prompt list

Primary outcome measures

  • Effectiveness - Self-Efficacy in managing patient-provider interactions - Quantitative Scale [Time frame: From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2)]
Secondary outcome measures (10)
  • Reach - Number and Proportion [Time frame: At start of Participation]
  • Effectiveness - Self-Efficacy in managing patient-provider interactions - Quantitative Scale [Time frame: From Pre-Clinic (Time 2) to end of Post-Clinic Visit (Time 3) up to 3 months.]
  • Effectiveness - Knowledge - Quantitative Scale [Time frame: From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2)]
  • Effectiveness - Knowledge - Quantitative Scale [Time frame: From Pre-Clinic Visit (Time 2) to end of Post-Clinic Visit (Time 3) up to 3 months]
  • Effectiveness - Trust - Quantitative Scale [Time frame: From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2)]
  • Effectiveness - Trust - Quantitative Scale [Time frame: From Pre-Clinic Visit (Time 2) to end of Post-Clinic Visit (Time 3) up to 3 months]
  • Effectiveness - distress - Quantitative Scale [Time frame: From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2)]
  • Effectiveness - distress - Quantitative Scale [Time frame: From Pre-Clinic Visit (Time 2) to end of Post-Clinic Visit (Time 3) up to 3 months]
  • Adoption - Number and Proportion [Time frame: At start of Participation]
  • Implementation of the Intervention [Time frame: From Baseline (Time 1) to up to 3 months]

Eligibility criteria

Inclusion criteria

  • Age > or equal to 18 years
  • Appointment to see a provider at a Karmanos Cancer Institute-McLaren or a medical encounter at McLaren Center for Research and Innovation (MCRI) site for medical/systemic treatment
  • Potentially eligible for a clinical trial
  • Speak and read English well enough to be able to understand consent documents and complete surveys

Exclusion criteria

  • Not able to complete study documents on their own physically or cognitively

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Health services research

Study locations

United States · 8 centers
  • Karmanos Cancer Institute at McLaren Bay Region — Bay City
  • Karmanos Cancer Institute at McLaren Clarkston — Clarkston
  • Karmanos Cancer Institute at McLaren Greater Lansing — Lansing
  • Karmanos Cancer Institute at McLaren Lapeer — Lapeer
  • Karmanos Cancer Institute at McLaren Macomb — Mount Clemens
  • Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center — Mount Pleasant
  • Karmanos Cancer Institute at McLaren Northern Michigan — Petoskey
  • Karmanos Cancer Institute at McLaren Port Huron — Port Huron

Identifiers

NCT: NCT07343297 · 2025-082

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗